ライフサイエンスコーパス: sense oligonucleotide

1 n, as well as by transfection of a FLIP anti-sense oligonucleotide.

2 ntical base composition or the complementary sense oligonucleotide.

3 s was prevented by cotransfection with cPLA2 sense oligonucleotide.

4 tex beads compared to those treated with the sense oligonucleotides.

5 hen to compared with oocytes coinjected with sense oligonucleotides.

6 8 hours in the presence of OP-1 antisense or sense oligonucleotides.

7 when assisted by a dumbbell-like fluorescent sensing oligonucleotide.

8 of multiple combinations of fluorophores and sensing oligonucleotides.

9 Gelsolin anti-sense oligonucleotide (20 microM) treatment of NR6 cells

10 Furthermore, antisense and sense oligonucleotides against alpha1A did not affect R-

11 bating the cells with antisense but not with sense oligonucleotides against CREB.

12 against G alpha i2, but not by injection of sense oligonucleotides against G alpha i2.

13 CT and NIH3T3 fibroblast lines by using anti-sense oligonucleotides against PTEN.

14 Injection of antisense (or sense) oligonucleotides against G alpha i1, G alpha i3 a

15 -subunits or with injection of antisense (or sense) oligonucleotides against these G proteins.

16 s proof of concept, we designed a battery of sensing oligonucleotides against specific regions of the

17 reatment with pharmacologic grade DNMT1 anti-sense oligonucleotides and STAT3 small-interfering RNA i

18 s were supplemented with either antisense or sense oligonucleotides and whole-cell patch clamp record

19 ucleotides to the Ln-5 gamma2 chain (but not sense oligonucleotides), and antibodies to MMP-2 or MT1-

20 ndependent PLA2 inhibitor (HELSS), an 85-kDa sense oligonucleotide, and a nonrelevant scrambled contr

21 Pre-clinical data from knockouts, anti-sense oligonucleotides, and siRNA for Nav1.3, 1.7, 1.8,

22 Parallel studies utilized the corresponding sense oligonucleotide as a control.

23 eolar macrophages were also treated with the sense oligonucleotides as the control.

24 Human LF were treated with circ-RORbeta anti-sense oligonucleotide (ASO) +/- ethanol, and samples wer

25 d2WS25/- mice were treated with an mTOR anti-sense oligonucleotide (ASO) that blocks mTOR expression

26 Anti-sense oligonucleotides (ASOs) are modified synthetic sin

27 Here, anti-sense oligonucleotides (ASOs) were used to disrupt nativ

28 er treatment with antisense but not reversed-sense oligonucleotides both in vivo and in vitro.

29 n synthesis were blocked by a TGF-beta1 anti-sense oligonucleotide, by antibodies to TGF-beta, and in

30 We further show that a miR-27a anti-sense oligonucleotide, by opposing the effects of mir-27

31 This study demonstrates that a methylated sense oligonucleotide can be used to induce epigenetic c

32 strongly suggest that topically applied anti-sense oligonucleotides can be delivered to target sites

33 A 37-nt S1 RNA sense oligonucleotide, containing two distinct stem-loop

34 of zebrafish embryos with a morpholino anti-sense oligonucleotide corresponding to the ortholog of N

35 ure of LNCaP cell with antisense and not the sense oligonucleotide decreased the HPG-1 mRNA levels an

36 with EphA4 levels in feather buds using anti-sense oligonucleotides, demonstrating a severe effect on

37 In parallel experimental groups, cPLA2 sense oligonucleotides did not affect cPLA2 protein expr

38 replicated HS effects; 2) antisense, but not sense, oligonucleotides directed against rat HSP70 parti

39 whereas untreated cells or cells exposed to sense oligonucleotides displayed a mature INa.

40 enzyme to test nuclease sensitivity of anti-sense oligonucleotide drugs.

41 Phosphorothioated antisense (AS) or sense oligonucleotides for Nox4 were administered for 2

42 h muscle cells (SMC) with antisense, but not sense, oligonucleotides for iPLA(2) impaired thapsigargi

43 FOXP3 anti-sense oligonucleotide (FOXP3-ASO), repolarises Tregs to

44 clin D1 and DNA synthesis, whereas cyclin D1 sense oligonucleotides had no effect.

45 Moreover, MAPK antisense, but not sense, oligonucleotide inhibited IL-6-induced proliferat

46 The antisense, but not the sense, oligonucleotide inhibited PKCbetaII activation an

47 with CD and then incubated with a Smad7 anti-sense oligonucleotide (knock down).

48 ng PNA-RNA-RBP complex can be isolated using sense oligonucleotide magnetic beads, and the RBPs can t

49 48 h, whereas cells treated with diluent or sense oligonucleotides maintained tight perinuclear aggr

50 ons suggest that cholesterol-conjugated anti-sense oligonucleotides may offer a novel approach to inh

51 re of MM cells with RB antisense, but not RB sense, oligonucleotide (ODN) triggered IL-6 secretion an

52 We also used antisense and sense oligonucleotides of the cytoplasmic dynein heavy c

53 d with docetaxel alone or docetaxel and EGFR sense oligonucleotides (P < 0.05).

54 red to a 13% reduction in cells treated with sense oligonucleotides (P=0.03).

55 Preincubation of CF-T43 cells with CFTR anti-sense oligonucleotides prevented an increase in 36Cl- ef

56 sfected or microinjected with surviving anti-sense oligonucleotides produce significantly more polypl

57 targeted lipid nanoparticle delivery of anti-sense oligonucleotides, proved to be sufficient to overc

58 cultures by a specific antisense, but not a sense, oligonucleotide reduced PAR4AP-induced TNF-alpha.

59 An anti-sense oligonucleotide to feline SP (SP-asODN) was inject

60 ing of antisense (4003W94) to a biotinylated sense oligonucleotide to form a double-stranded nucleic

61 ition of phosphothiolated antisense, but not sense oligonucleotides to C/EBP epsilon, decreased clona

62 mary cortical neurons with antisense but not sense oligonucleotides to GAPDH prevents cell death.

63 itching to chow diet and treatment with LDLR sense oligonucleotides to induce atherosclerosis regress

64 ed sexual behavior in rodents, antisense and sense oligonucleotides to PR and D(1)R were administered

65 Preincubation of CD34+ marrow cells with two sense oligonucleotides to Smad5 did not reverse the inhi

66 4+ cells were decreased by antisense but not sense oligonucleotides to Smad5.

67 Anti-sense oligonucleotides to the cloned sequence dramatical

68 Anti-sense but not sense oligonucleotides to the human Nck resumed the NGF-

69 in/gelatin matrix in vitro compared with LOX sense oligonucleotide-treated and untreated controls.

70 anges in the current expression were seen in sense oligonucleotide-treated cells (-11.3 +/- 3.2 pA/pF

71 clinically and histologically than control (sense) oligonucleotide-treated areas.

72 nin in the presence of antisense or reversed-sense oligonucleotides using a quantitative adhesion ass

73 ells, whereas down-regulation of ALY by anti-sense oligonucleotides virtually eliminates TCR alpha en

74 ressing cells or cells treated with PS1 anti-sense oligonucleotides were less capable of taking up Ab

75 Two antisense and two control sense oligonucleotides were synthesized and introduced e

76 he growth of these cells, whereas random and sense oligonucleotides were without effect.

77 L-1beta-induced PGE2 formation while control sense oligonucleotides were without effect.